67 results
8-K
EX-99.1
XENE
Xenon Pharmaceuticals Inc
9 May 23
Xenon Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
4:23pm
program, supported by a robust data package and validated mechanism, including efficacy data from our Phase 2b X-TOLE clinical trial and read-outs from
8-K
EX-99.1
dscw 6hx3gpf
8 Nov 22
Xenon Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
4:07pm
424B5
2xp0n
23 Jun 22
Prospectus supplement for primary offering
4:09pm
424B5
y1oz8n
22 Jun 22
Prospectus supplement for primary offering
4:05pm
8-K
EX-99.1
vk1o7fu nc
21 Jun 22
Xenon Pharmaceuticals Announces Positive Outcome of End-of-Phase 2 Meeting with the FDA
7:03am
424B5
vbqlwbtzc38qf4sat5
1 Mar 22
Prospectus supplement for primary offering
5:12pm
424B5
hb6nf0p z33sz0
6 Oct 21
Prospectus supplement for primary offering
5:05pm
424B5
iw5a7q91
4 Oct 21
Prospectus supplement for primary offering
5:27pm